NCT01345799

Brief Summary

In Crohn's Disease Patients

  • To evaluate the efficacy of TRK-170
  • To evaluate the PK characteristics of TRK-170
  • To assess the safety of TRK-170

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
123

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Apr 2011

Typical duration for phase_2

Geographic Reach
12 countries

12 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

April 28, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 2, 2011

Completed
2.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2014

Completed
Last Updated

June 12, 2014

Status Verified

June 1, 2014

First QC Date

April 28, 2011

Last Update Submit

June 11, 2014

Conditions

Keywords

Crohn's Disease Activity IndexCrohn's DiseaseInflammatory Bowel Disease

Outcome Measures

Primary Outcomes (1)

  • Crohn's Disease Activity Index

    8 weeks (treatment), 4 weeks (follow-up)

    12 weeks

Study Arms (4)

TRK-170 Low Dose

EXPERIMENTAL
Drug: TRK-170

TRK-170 Middle Dose

EXPERIMENTAL
Drug: TRK-170

TRK-170 High Dose

EXPERIMENTAL
Drug: TRK-170

Placebo

PLACEBO COMPARATOR
Drug: Placebo

Interventions

TRK-170 High DoseTRK-170 Low DoseTRK-170 Middle Dose
Placebo

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patient has a diagnosis of Crohn's Disease before screening
  • Patient has stable disease activity

You may not qualify if:

  • Patient has had a clinically significant illness prior to screening
  • Patient with clinically significant deviations in laboratory values

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Belgium

Belgium, Belgium

Location

Bulgaria

Bulgaria, Bulgaria

Location

Czech Republic

Czech Republic, Czechia

Location

France

France, France

Location

Hungary

Hungary, Hungary

Location

Latvia

Latvia, Latvia

Location

The Netherlands

The Netherlands, Netherlands

Location

Norway

Norway, Norway

Location

Poland

Poland, Poland

Location

Romania

Romania, Romania

Location

Serbia

Serbica, Serbia

Location

Sweden

Sweden, Sweden

Location

Ukraine

Ukraine, Ukraine

Location

MeSH Terms

Conditions

Crohn DiseaseInflammatory Bowel Diseases

Condition Hierarchy (Ancestors)

GastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 28, 2011

First Posted

May 2, 2011

Study Start

April 1, 2011

Study Completion

April 1, 2014

Last Updated

June 12, 2014

Record last verified: 2014-06

Locations